What is the recommended treatment for a male patient with co‑infection of Chlamydia trachomatis and Neisseria gonorrhoeae?

Treatment for Chlamydia and Gonorrhea Co-infection in Males

For a male patient with confirmed or suspected co-infection of Chlamydia trachomatis and Neisseria gonorrhoeae, treat with ceftriaxone 500 mg IM once PLUS doxycycline 100 mg orally twice daily for 7 days.

Current Evidence-Based Approach

The most recent high-quality evidence from 2020-2022 demonstrates a critical shift in gonorrhea treatment recommendations 1, 2. The 2020 CDC update increased ceftriaxone dosing from 125 mg to 500 mg IM as monotherapy for gonorrhea, driven by antimicrobial stewardship concerns and rising azithromycin resistance (nearly 5% of isolates showing elevated MICs by 2018) 1.

Treatment Regimen

For gonorrhea:

• Ceftriaxone 500 mg IM in a single dose 1, 2

For chlamydia (when co-infection not excluded):

• Doxycycline 100 mg orally twice daily for 7 days 2
• Alternative: Azithromycin 1 g orally single dose 3

Key Rationale

The dual-therapy approach remains essential because:

1. High co-infection rates persist: Studies show 20% of men with gonorrhea have concurrent chlamydia 4. When treating gonorrhea presumptively, chlamydia prevalence reaches 19% in men who wouldn't otherwise receive chlamydia treatment 4.

2. Same-day treatment is standard: Approximately 86% of treatments occur on the same day as testing 5, meaning most patients receive empiric therapy before culture results return.

3. Ceftriaxone resistance remains low in the US: Despite international treatment failures, US surveillance shows <0.1% of isolates with elevated ceftriaxone MICs 1.

Site-Specific Considerations

Pharyngeal Infections

Pharyngeal gonorrhea is harder to eradicate than urogenital infections 6. The same regimen applies:

• Ceftriaxone 500 mg IM once
• PLUS doxycycline 100 mg twice daily for 7 days (if chlamydia not excluded) 3

Critical caveat: Quinolones should NOT be used for men who have sex with men (MSM) or those with recent travel to areas with quinolone-resistant gonorrhea 3.

Special Populations

Cephalosporin Allergy

• Spectinomycin 2 g IM (if available) 3, 7
• Major limitation: Only 52% effective against pharyngeal infections 6, 3, 6
• Requires pharyngeal culture 3-5 days post-treatment to verify eradication 3
• No recommended alternative exists for pharyngeal gonorrhea in cephalosporin-allergic patients 1

Adolescents

• Same adult regimen applies
• Avoid quinolones in patients <18 years (though evidence of harm is limited) 6

HIV-Positive Patients

• Use identical treatment regimens as HIV-negative patients 6, 7

Follow-Up Protocol

Test of Cure

• Not routinely needed after treatment with recommended regimens 6, 3
• Only indicated if symptoms persist or reinfection suspected 3

Retesting Strategy

• Retest at 3 months regardless of partner treatment status 3
• High reinfection rates (not treatment failure) drive this recommendation 3
• If patient doesn't return at 3 months, test at next visit within 12 months 3

Persistent Symptoms

Evaluate for:

• Treatment failure (rare with recommended regimens) 6
• Reinfection (most common cause) 6, 3
• Other organisms (Mycoplasma genitalium, Trichomonas vaginalis) 8
• Perform culture with antimicrobial susceptibility testing 3

Partner Management

All sexual partners within 60 days before symptom onset or diagnosis must be evaluated and treated for both gonorrhea and chlamydia 6, 3. If last intercourse was >60 days ago, treat the most recent partner 3.

Expedited Partner Therapy

• Acceptable for heterosexual partners when direct evaluation unlikely 3
• Not recommended for MSM due to high risk of undiagnosed co-infections (HIV, syphilis) 3
• Must include treatment for both gonorrhea and chlamydia 3

Common Pitfalls to Avoid

1. Don't use azithromycin monotherapy for gonorrhea: Insufficient efficacy and promotes resistance 6, 1

2. Don't use quinolones in MSM: High rates of quinolone-resistant gonorrhea in this population 3

3. Don't skip chlamydia treatment: Even with negative testing, consider empiric treatment given high co-infection rates and same-day treatment patterns 5, 4

4. Don't use the old 125 mg ceftriaxone dose: Updated to 500 mg in 2020 1, 2

5. Don't forget to instruct abstinence: Patients must avoid sexual intercourse until therapy completed and both partners are symptom-free 6, 3